Literature DB >> 25412392

Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2.

Carol L Kosary1, Sean F Altekruse, Jennifer Ruhl, Richard Lee, Lois Dickie.   

Abstract

BACKGROUND: The objectives of this article are to assess the completeness of the data collected on site-specific factors (SSFs) as a part of Collaborative Stage (CS) version 2 and the impact of the transition from the American Joint Committee on Cancer's (AJCC) 6th to 7th edition guidelines on stage distribution.
METHODS: Incidence data for melanomas of the skin from 18 Surveillance, Epidemiology, and End Results (SEER) registries (SEER-18) were analyzed. Percentages of unknown cases for 7 SSFs were examined, along with staging trends from 2004 to 2010 and differences in AJCC 6th and 7th edition stage distributions for 2010 cases.
RESULTS: Fewer than 10% of cases were coded as unknown for SSFs 1 (measured thickness), 2 (ulceration), and 3 (lymph node metastasis). For the remaining SSFs, 36-81% of cases were coded as unknown. Stage distributions were relatively consistent across time and between the AJCC 6th and 7th editions, with the exception of stage IA and stage INOS (not otherwise specified), for which a shift in cases was observed between the AJCC 6th and 7th edition guidelines fOR 2010 cases.
CONCLUSIONS: A shift of cases out of stage IA and into stage INOS was observed between the AJCC 6th and 7th edition guidelines for 2010 cases. This was attributed to the high number of cases coded as unknown for SSF7 (primary tumor mitotic count/rate). The percentage of cases coded as unknown varied by SSF. Data completeness presents an issue for SSFs introduced in CS version 2.
© 2014 American Cancer Society.

Entities:  

Keywords:  cancer staging; cutaneous; melanoma; skin

Mesh:

Year:  2014        PMID: 25412392     DOI: 10.1002/cncr.29050

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium.

Authors:  Alexander J Stratigos; Maria Concetta Fargnoli; Arcangela De Nicolo; Ketty Peris; Susana Puig; Efthymia Soura; Chiara Menin; Donato Calista; Paola Ghiorzo; Mario Mandala; Daniela Massi; Monica Rodolfo; Laura Del Regno; Irene Stefanaki; Helen Gogas; Veronique Bataille; Margaret A Tucker; David Whiteman; Eduardo Nagore; Maria Teresa Landi
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-09-14       Impact factor: 6.166

2.  Re-excision within a radius of 2 cm in patients with melanoma of the skin - sufficient for local oncological radicalness.

Authors:  Strahil Asenov Strashilov; Angel Danchev Yordanov; Mariela Borisova Vasileva-Slaveva; Assia Andrianova Konsoulova
Journal:  Arch Med Sci       Date:  2020-07-08       Impact factor: 3.707

3.  Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.

Authors:  Mengze Hao; Gang Zhao; Xiaoling Du; Yun Yang; Jilong Yang
Journal:  Tumour Biol       Date:  2016-02-04

4.  Metastasis suppressor NME1 regulates melanoma cell morphology, self-adhesion and motility via induction of fibronectin expression.

Authors:  Marián Novak; Mary Kathryn Leonard; Xiuwei H Yang; Anjan Kowluru; Alexey M Belkin; David M Kaetzel
Journal:  Exp Dermatol       Date:  2015-04-27       Impact factor: 3.960

Review 5.  The Prognostic Value of Age, Sex, and Subsite in Cutaneous Head and Neck Melanoma: A Clinical Review of Recent Literature.

Authors:  Sameep Kadakia; David Chan; Moustafa Mourad; Yadranko Ducic
Journal:  Iran J Cancer Prev       Date:  2016-06-08

6.  Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis.

Authors:  Weidong Shen; Naoko Sakamoto; Limin Yang
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

7.  MicroRNA-150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4.

Authors:  Jianji Wan; Jie Yang; Yueshen Huang; Liehua Deng
Journal:  Oncol Lett       Date:  2017-11-20       Impact factor: 2.967

8.  4-Thiazolidinone derivative Les-3833 effectively inhibits viability of human melanoma cells through activating apoptotic mechanisms.

Authors:  Nataliya Finiuk; Nataliya Boiko; Olga Klyuchivska; Lesya Коbylinska; Iryna Kril; Borys Zimenkovsky; Roman Lesyk; Rostyslav Stoika
Journal:  Croat Med J       Date:  2017-04-14       Impact factor: 1.351

9.  Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process-A systematic review.

Authors:  Antonino Guerrisi; Emiliano Loi; Sara Ungania; Michelangelo Russillo; Vicente Bruzzaniti; Fulvia Elia; Flora Desiderio; Raffaella Marconi; Francesco Maria Solivetti; Lidia Strigari
Journal:  Cancer Med       Date:  2020-01-17       Impact factor: 4.452

10.  Functional assessment of cancer therapy questionnaire for melanoma in the Serbian population: A factor analytic approach.

Authors:  Suzana Matkovic; Jelena Dotlic; Tatjana Gazibara; Gorica Maric; Vladimir Nikolic; Natasa Maksimovic
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.